Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis

Published:2022-11 Issue:11 Volume:28 Page:1282-1291
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Berrios Kevin¹,Burum Alexandra¹,Jeong Eunae¹,Zhong Lixian¹²³

Affiliation:

1. Texas A&M Irma Lerma Rangel College of Pharmacy, College Station.

2. Department of Clinical Pharmacy, University of California, San Francisco.

3. Houston Methodist Research Institute, TX.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference26 articles.

1. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

2. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

3. Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now?

4. Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects

5. Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP